Boulevard Bio
Boulevard Bio develops multi-specific antibody medicines for B cell-driven autoimmune diseases on targeted therapies.
$65M Seed ·
Source: BioPharm International
Funding history ↓Signals
Website registeredFeb 3, 2025 (21 months old)
Funding rounds
| Date | Round | Amount | Lead | Source |
|---|---|---|---|---|
| Seed | $65M | — | BioPharm International |
Timeline
- Website created
Founders and team
FN
Frank Nestle Scientific Co-Foundersource: boulevardbio.comGS
Georg Schett Scientific Co-Foundersource: boulevardbio.com
Investors
Companies like Boulevard Bio
AAbcuro$66M Series B+ · Aug 2026
AAsher Bio$55M Series B+ · Apr 2024
ZZag BioSeries A
FFlip TherapeuticsSeed · Sep 2026
CCoultreon$125M Series A · Apr 2026EExcalipoint TherapeticsSeed · Mar 2026
Sources and API
Every amount links to the page it came from. * Estimated from an accelerator's published standard deal, not a company-specific disclosure. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/boulevard-bio (get a free API key).